Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty
07:09pm, Thursday, 08'th Jan 2026
AnaptysBio said on Thursday it filed a partial motion to dismiss a claim by GSK's oncology unit, which alleges the biotech breached their contract, escalating a legal dispute over royalties tied to sa
Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
06:00pm, Thursday, 08'th Jan 2026
SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, filed a partial motion to
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies
01:36pm, Thursday, 08'th Jan 2026
GSK's bepirovirsen hit primary endpoints in two phase III trials, boosting hopes for a functional cure in chronic hepatitis B patients.
GSK Licenses Noetik's AI Foundation Models in Anchor Partnership to Transform Cancer Therapeutic Research and Development
09:00am, Thursday, 08'th Jan 2026
SAN FRANCISCO--(BUSINESS WIRE)-- #GSK--GSK licenses Noetik's AI foundation models in anchor partnership to transform cancer therapeutic research and development.
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies
11:48am, Wednesday, 07'th Jan 2026
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) partner GSK Plc (NYSE: GSK) on Wednesday shared data from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, of bepirovirsen, an investigational antisense ol
GSK Scores Phase III Win in Hep B
10:50am, Wednesday, 07'th Jan 2026
GSK (GSK) just posted the kind of late-stage result drugmakers hope for. The company said its experimental hepatitis B treatment, bepirovirsen, delivered positi
GSK reports breakthrough trial results for hepatitis B drug
02:54am, Wednesday, 07'th Jan 2026
GSK PLC (LSE:GSK, NYSE:GSK) said on Wednesday that a potential new treatment for chronic hepatitis B had delivered positive late-stage trial results, raising the prospect of a shorter, more effective
GSK reports breakthrough trial results for hepatitis B drug
02:51am, Wednesday, 07'th Jan 2026
GSK PLC (LSE:GSK, NYSE:GSK) said on Wednesday that a potential new treatment for chronic hepatitis B had delivered positive late-stage trial results,...
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, evaluating the safet
GSK's chronic hepatitis B treatment meets main goal in key studies
02:09am, Wednesday, 07'th Jan 2026
GSK's experimental drug to treat chronic hepatitis B infection met the main goals in two closely watched studies, the drugmaker said on Wednesday, bringing the company a step closer to making a functi
GSK Wins Japan Approval for Exdensur
12:48pm, Tuesday, 06'th Jan 2026
GSK (GSK) notched a solid regulatory win in Japan, with health authorities approving Exdensur for patients with severe asthma and chronic rhinosinusitis with na
GSK's asthma treatment gets greenlight in Japan
04:50am, Tuesday, 06'th Jan 2026
GSK PLC (LSE:GSK, NYSE:GSK) said Japan has approved Exdensur (depemokimab) to treat severe or refractory bronchial asthma and chronic rhinosinusitis with nasal polyps. The big-cap drugmaker said the
GSK's asthma treatment gets greenlight in Japan
04:38am, Tuesday, 06'th Jan 2026
GSK PLC (LSE:GSK, NYSE:GSK) said Japan has approved Exdensur (depemokimab) to treat severe or refractory bronchial asthma and chronic rhinosinusitis with...
First Look: 2026 Outlook, Buffett Exit, Fed Split, Dollar Slide
07:37am, Thursday, 01'st Jan 2026
Stock News Street sets 2026 expectations: Wall Street sees the S&P 500 posting modest-to-mid-teens gains in 2026 after a 16.39% rise in 2025, with AI leaders li
Pfizer and GSK Lead 2026 U.S. Drug Price Hikes
11:03am, Wednesday, 31'st Dec 2025
Pfizer (PFE) and GlaxoSmithKline (GSK) are among the top drugmakers planning price increases for hundreds of branded medicines in the U.S. next year, according
